Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 May;25(5):603–606. doi: 10.1128/aac.25.5.603

Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.

R D Blevins, C E Halstenson, N G Salem, G R Matzke
PMCID: PMC185596  PMID: 6732227

Abstract

The pharmacokinetics of vancomycin were studied in four patients on continuous ambulatory peritoneal dialysis. After a single intravenous infusion of 10 mg/kg of total body weight, multiple blood, urine, and dialysate samples were collected during a 72-h evaluation period. The steady-state volume of distribution was 0.73 +/- 0.07 (mean +/- standard deviation) liters/kg with a beta half-life of 90.2 +/- 24.2 h. The continuous ambulatory peritoneal dialysis clearance of vancomycin was 1.35 +/- 0.35 ml/min, and the serum clearance was 6.4 +/- 1.1 ml/min. Peritoneal dialysate concentrations of vancomycin were rapidly attained after the intravenous infusion and averaged 2.2 +/- 0.7 mg/liter throughout the 72-h observation period. A loading dose of 23 mg/kg followed by a maintenance dose of 17 mg/kg every 7 days should attain and maintain therapeutic serum and dialysate concentrations. More frequent dosing may be necessary for less susceptible organisms.

Full text

PDF
603

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayus J. C., Eneas J. F., Tong T. G., Benowitz N. L., Schoenfeld P. Y., Hadley K. L., Becker C. E., Humphreys M. H. Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis. Clin Nephrol. 1979 Mar;11(3):129–132. [PubMed] [Google Scholar]
  2. Blouin R. A., Bauer L. A., Miller D. D., Record K. E., Griffen W. O., Jr Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982 Apr;21(4):575–580. doi: 10.1128/aac.21.4.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bunke C. M., Aronoff G. R., Brier M. E., Sloan R. S., Luft F. C. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1983 Nov;34(5):631–637. doi: 10.1038/clpt.1983.225. [DOI] [PubMed] [Google Scholar]
  4. Cunha B. A., Ristuccia A. M. Clinical usefulness of vancomycin. Clin Pharm. 1983 Sep-Oct;2(5):417–424. [PubMed] [Google Scholar]
  5. Esposito A. L., Gleckman R. A. Vancomycin. A second look. JAMA. 1977 Oct 17;238(16):1756–1757. doi: 10.1001/jama.238.16.1756. [DOI] [PubMed] [Google Scholar]
  6. Eykyn S., Phillips I., Evans J. Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis. Br Med J. 1970 Jul 11;3(5714):80–82. doi: 10.1136/bmj.3.5714.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fekety R. Vancomycin. Med Clin North Am. 1982 Jan;66(1):175–181. doi: 10.1016/s0025-7125(16)31451-1. [DOI] [PubMed] [Google Scholar]
  8. Geraci J. E., Hermans P. E. Vancomycin. Mayo Clin Proc. 1983 Feb;58(2):88–91. [PubMed] [Google Scholar]
  9. Glew R. H., Pavuk R. A., Shuster A., Alfred H. J. Vancomycin pharmacokinetics in patients undergoing chronic intermittent peritoneal dialysis. Int J Clin Pharmacol Ther Toxicol. 1982 Dec;20(12):559–563. [PubMed] [Google Scholar]
  10. Krogstad D. J., Moellering R. C., Jr, Greenblatt D. J. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol. 1980 Apr;20(4 Pt 1):197–201. doi: 10.1002/j.1552-4604.1980.tb01696.x. [DOI] [PubMed] [Google Scholar]
  11. Krothapalli R. K., Senekjian H. O., Ayus J. C. Efficacy of intravenous vancomycin in the treatment of gram-positive peritonitis in long-term peritoneal dialysis. Am J Med. 1983 Aug;75(2):345–348. doi: 10.1016/0002-9343(83)91215-9. [DOI] [PubMed] [Google Scholar]
  12. Magera B. E., Arroyo J. C., Rosansky S. J., Postic B. Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis. Antimicrob Agents Chemother. 1983 May;23(5):710–714. doi: 10.1128/aac.23.5.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mean F., Pellaton M., Magrini G. Study on the binding of dihydrotestosterone, testosterone and oestradiol with sex hormone binding globulin. Clin Chim Acta. 1977 Oct 1;80(1):171–180. doi: 10.1016/0009-8981(77)90276-5. [DOI] [PubMed] [Google Scholar]
  14. Morris A. J., Bilinsky R. T. Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis. Am J Med Sci. 1971 Aug;262(2):87–92. doi: 10.1097/00000441-197108000-00003. [DOI] [PubMed] [Google Scholar]
  15. Nielsen H. E., Sørensen I., Hansen H. E. Peritoneal transport of vancomycin during peritoneal dialysis. Nephron. 1979;24(6):274–277. doi: 10.1159/000181735. [DOI] [PubMed] [Google Scholar]
  16. Pancorbo S., Comty C. Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis. Nephron. 1982;31(1):37–39. doi: 10.1159/000182611. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES